Researchers identify potential patient safety risks among methadone maintenance treatment patients

Jul 08, 2009

Boston Medical Center (BMC) researchers have identified potential safety risks among methadone maintenance treatment (MMT) patients due to the quantity and accuracy of medical record documentation. Improved communication and coordination among substance use treatment and medical providers could mitigate and manage the potential adverse effects of methadone and interacting medications. The BMC study appears in the July issue of Journal of General Internal Medicine.

MMT is a chronic therapy for opioid dependence, a chronic relapsing disease that often requires lifelong treatment. MMT typically is provided separately from medical care. Ideally, when patients in MMT engage in outpatient or inpatient medical care, treating physicians are aware of MMT and document both on the medication list and opioid dependence on the medical problem list. When this is not done, there is a chance for medication-methadone interactions, which could potentially contribute to clinically significant adverse events, including cardiac arrhythmias, overdoses and decreased cognitive function.

BMC researchers aimed to identify potential patient safety risks among MMT patients engaged in medical care by evaluating the frequency that opioid dependence and MMT documentation were missing in medical records and characterizing potential medication-methadone interactions.

The researchers found documentation of opioid dependence diagnosis was missing from the medical record in 30 percent of subjects; documentation of MMT was missing from either the last discharge summary or last primary care note in 11 percent of subjects; among subjects seen by a primary care doctor, documentation of MMT was missing in 7 percent; among subjects discharged from the inpatient hospital, documentation of MMT was missing in 10 percent. Sixty-nine percent of the study subjects were taking at least one medication that potentially interacted with methadone and 19 percent were taking three or more potentially interacting medications.

"Among patients receiving MMT and medical care at different sites, documentation of opioid dependence and MMT in the occurs for the majority, but is missing in a substantial number of patients," said lead author Alexander Walley, MD, MSc, general internist in the Clinical Addiction Research and Education Unit at BMC and assistant professor of medicine at Boston University School of Medicine. "Most of these patients are taking prescribed medications that potentially interact with methadone. This study demonstrates opportunities to improve communication, care coordination, and patient safety among patients receiving medical and substance use treatment."

Source: Boston University Medical Center

Explore further: Face transplants change lives, identity

add to favorites email to friend print save as pdf

Related Stories

New guidelines for prescribing opioid pain drugs published

Feb 10, 2009

A prestigious panel of pain-management experts representing the American Pain Society (APS) www.ampainsoc.org and the American Academy of Pain Medicine (AAPM) has published the first comprehensive clinical practice guidel ...

PTSD associated with more, longer hospitalizations

Mar 27, 2008

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) have found post-traumatic stress disorder (PTSD) is associated with more hospitalizations, longer hospitalizations and greater mental ...

Recommended for you

Face transplants change lives, identity

13 hours ago

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

User comments : 0